Navigation überspringen
Universitätsbibliothek Heidelberg
Status: Bibliographieeintrag

Verfügbarkeit
Standort: ---
Exemplare: ---
heiBIB
 Online-Ressource
Verfasst von:Li, Shiyue [VerfasserIn]   i
 Wang, Guangfa [VerfasserIn]   i
 Wang, Changhui [VerfasserIn]   i
 Gao, Xinglin [VerfasserIn]   i
 Jin, Faguang [VerfasserIn]   i
 Yang, Huaping [VerfasserIn]   i
 Han, Baohui [VerfasserIn]   i
 Zhou, Rui [VerfasserIn]   i
 Chen, Chengshui [VerfasserIn]   i
 Chen, Liangan [VerfasserIn]   i
 Bai, Chunxue [VerfasserIn]   i
 Shen, Huahao [VerfasserIn]   i
 Herth, Felix [VerfasserIn]   i
 Zhong, Nanshan [VerfasserIn]   i
Titel:The REACH trial
Titelzusatz:a randomized controlled trial assessing the safety and effectiveness of the Spiration® Valve System in the treatment of severe emphysema
Verf.angabe:Shiyue Li, Guangfa Wang, Changhui Wang, Xinglin Gao, Faguang Jin, Huaping Yang, Baohui Han, Rui Zhou, Chengshui Chen, Liangan Chen, Chunxue Bai, Huahao Shen, Felix J. F. Herth, Nanshan Zhong
Jahr:2019
Jahr des Originals:2018
Umfang:12 S.
Teil:volume:97
 year:2019
 number:5
 pages:416-427
 extent:12
Fussnoten:Published online: December 14, 2018 ; Gesehen am 13.11.2019
Titel Quelle:Enthalten in: Respiration
Ort Quelle:Basel : Karger, 1944
Jahr Quelle:2019
Band/Heft Quelle:97(2019), 5, Seite 416-427
ISSN Quelle:1423-0356
Abstract:<b><i>Background:</i></b> Chronic obstructive pulmonary disease (COPD) has become a leading cause of morbidity and mortality in China, with tobacco smoke, air pollution, and occupational biohazards being the major risk factors. <b><i>Objectives:</i></b> The REACH trial is a multicenter, prospective, randomized controlled trial undertaken in China to assess the safety and effectiveness of the Spiration® Valve System (SVS) compared to standard medical care in COPD patients with severe emphysema. <b><i>Methods:</i></b> Patients with severe airflow obstruction, hyperinflation, and severe dyspnea with interlobar fissure integrity were evaluated for enrollment. A total of 107 subjects were randomized in a 2: 1 allocation ratio to either the treatment group (SVS valves and medical management) or the control group (medical management alone). <b><i>Results:</i></b> The 3-month primary endpoint showed statistically significant improvement in forced expiratory volume in 1 s in the treatment group compared to the control group (0.104 ± 0.18 vs. 0.003 ± 0.15 L, <i>p</i> = 0.001), with the difference being durable through 6 months. Statistically significant target lobe volume reduction was achieved at 3 months (mean change 684.4 ± 686.7 mL) and through 6 months (757.0 ± 665.3 mL). Exercise function and quality of life measures improved in the treatment group, but showed a deterioration in the control group. The serious adverse event (SAE) rate was 33% in the treatment group and 24.2% in the control group. The predominance of SAEs were acute exacerbations of COPD in both groups. There was 1 death in the control group and no deaths in the treatment group. <b><i>Conclusion:</i></b> The SVS represents a novel approach for the treatment of severe emphysema with a clinically acceptable risk-benefit profile.
DOI:doi:10.1159/000494327
URL:Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.

Volltext ; Verlag ; Resolving-System: https://doi.org/10.1159/000494327
 Volltext: https://www.karger.com/Article/FullText/494327
 DOI: https://doi.org/10.1159/000494327
Datenträger:Online-Ressource
Sprache:eng
K10plus-PPN:1681803941
Verknüpfungen:→ Zeitschrift

Permanenter Link auf diesen Titel (bookmarkfähig):  https://katalog.ub.uni-heidelberg.de/titel/68454867   QR-Code
zum Seitenanfang